Working… Menu
Trial record 89 of 853 for:    Pancreatic Cancer AND Metastatic Pancreatic Cancer

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00245362
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : October 28, 2005
Information provided by:
Cell Genesys

Brief Summary:
To evaluate the safety and effectiveness of CG8020 and CG2505.

Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Cancer Nonresectable Pancreatic Cancer Biological: CG 8020 and CG 2505 Phase 2

Detailed Description:
To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced patients with nonresectable or metastatic adenocarcinoma of the pancreas

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Study Start Date : June 2002
Study Completion Date : June 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Safety
  2. Efficacy measured by clinical benefit response
  3. Progression-free survivial
  4. Overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic adenocarcinoma
  • Chemotherapy naïve or chemotherapy experienced pancreatic cancer

Exclusion Criteria:

  • Prior cancer vaccines or gene therapy
  • History of clinically significant autoimmune disease (eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis)
  • History of another malignancy in the past five years, except adequately treated non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix, unless approved by the Medical Monitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00245362

Layout table for location information
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
United States, Texas
US Oncology
Dallas, Texas, United States
Sponsors and Collaborators
Cell Genesys

Layout table for additonal information Identifier: NCT00245362     History of Changes
Other Study ID Numbers: P-0011
First Posted: October 28, 2005    Key Record Dates
Last Update Posted: October 28, 2005
Last Verified: October 2005
Keywords provided by Cell Genesys:
cancer vaccine
pancreatic cancer
metastatic pancreatic cancer
unresectable pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases